Novartis is paying $575 million upfront for a drug that has only been through small, early human studies, plus options on whatever Abogen builds next.

That is the headline figure in a licensing and option agreement announced October 2, 2026 by Abogen Biosciences, a privately held mRNA developer based in Suzhou, China. Novartis gets exclusive worldwide rights to ABO2203, Abogen’s lead program. It also gets exclusive options on other programs built on Abogen’s RNA platform. If Novartis exercises every option, Abogen says it could collect up to about $7.2 billion more in milestone payments tied to development, regulatory, and sales targets, plus possible royalties.

For public-market investors, this is a Novartis (NYSE: NVS; SIX: NOVN) story. Abogen’s release gives no ticker, and BioTech Stocks Daily found no public listing for the company.

One caveat up front. The deal hasn’t closed. Abogen’s release describes the financial terms as part of a “proposed agreement,” subject to customary closing conditions that include regulatory clearances.

How ABO2203 Works

A T-cell engager (TCE) is an engineered antibody with two arms. One grabs a T cell, the immune system’s attack cell. The other grabs a target. For ABO2203, that target is CD19, a marker on B cells, the cells that make antibodies. Pull the two together and the T cell kills the B cell.

Approved TCEs are proteins made in a factory and given by infusion or injection. ABO2203 works differently. It delivers mRNA packaged in a lipid nanoparticle, the same basic delivery system used in mRNA COVID-19 vaccines, and the patient’s own cells then make the engager. Abogen argues this produces a slower, flatter rise in drug levels than a protein dose. That matters because the main safety risk with TCEs is cytokine release syndrome (CRS), an inflammatory reaction that can turn severe.

Why autoimmune disease? In conditions like lupus, B cells produce antibodies that attack the body’s own tissue. Clearing them out and letting fresh B cells grow back is the “immune reset” idea that Fiona Marshall, President of Biomedical Research at Novartis, pointed to in the release.

The Data So Far

It’s thin. And the deal release doesn’t cite any of it.

The most detailed figures come from Abogen’s April 2026 presentation at the American Association for Cancer Research (AACR) annual meeting. That first-in-human study enrolled patients with relapsed or refractory B-cell non-Hodgkin lymphoma, a blood cancer, and the presentation covered nine of them. Abogen reported no dose-limiting toxicities, no CRS, and no ICANS, a nerve-related side effect seen with TCEs. Response rates climbed with dose, from 33% to 67% to 100% across the low, middle, and high groups. With roughly three patients per group, each patient swings those percentages a lot.

In autoimmune disease, a paper published in Cell in September 2026 described three patients with refractory immune thrombocytopenia (ITP), in which the immune system destroys platelets, the cells that help blood clot. According to the authors, ABO2203 cleared B cells from the blood and bone marrow in all three, with complete platelet responses that held over six months. The wider investigator-initiated trial at Shanghai’s Ruijin Hospital (NCT06747156) had enrolled 16 patients with lupus, lupus nephritis, ITP, rheumatoid arthritis, and systemic sclerosis as of January 26, 2026. It is open-label and single-arm, with no comparison group.

That is early proof of concept. It is not evidence that ABO2203 works in lupus or any other specific disease, and the drug is not approved anywhere.

Checking the “First” Claim

Abogen CEO Bo Ying called ABO2203 the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases. Its autoimmune trial lists a start date of December 23, 2024. BioTech Stocks Daily did not find an earlier documented study of that kind, but could not independently confirm the claim, so read it as the company’s own characterization.

Note how narrow the wording is. ABO2203 is not the first T-cell engager tested in autoimmune disease. Nor is it the first mRNA-based approach there.

A Crowded Race to Reset B Cells

Cullinan Therapeutics (Nasdaq: CGEM) is running Phase 1 trials of CLN-978, a conventional protein CD19xCD3 engager, in lupus, rheumatoid arthritis, and Sjögren’s disease, and has promised multi-dose data across all three in the fourth quarter of 2026. Privately held Candid Therapeutics has said it is moving its engager cizutamig into global Phase 2 studies in two autoimmune indications. Cartesian Therapeutics (Nasdaq: RNAC) is further along still, with an mRNA-based CAR-T cell therapy, Descartes-08, in a Phase 3 trial for myasthenia gravis and topline data expected in the first quarter of 2027.

None of these programs has been tested head-to-head against ABO2203. The trials differ in design, disease, and patient population, so any comparison is suggestive at best.

What the Release Doesn’t Say

Quite a lot. Abogen didn’t disclose how many programs Novartis can option, what Novartis pays to exercise each option, how the $7.2 billion splits between ABO2203 and the option programs, or what royalty rates apply. That $7.2 billion only materializes if every option is exercised and every milestone is hit, which is rarely how licensing deals play out.

The release also doesn’t say whether Novartis will develop ABO2203 in autoimmune disease only, or in lymphoma as well, where most of the reported clinical data sits today.

Why the Upfront Stands Out

Novartis has shopped in China’s RNA sector before. In January 2024 it paid $185 million upfront for two clinical-stage RNAi cardiovascular programs from Argo Biopharmaceutical, then returned in 2025 with $160 million upfront for a broader collaboration. The Abogen upfront is more than three times either payment.

Abogen, founded in 2019, has raised about $1.13 billion across five funding rounds from investors including Hillhouse and Temasek, according to Tracxn. Its most advanced program is ABO1108, a freeze-dried mRNA shingles vaccine in Phase 3 trials in China. Ying said the Novartis deal shows the platform can reach beyond preventive vaccines.

What comes next: the deal closing, any terms Novartis chooses to disclose in its own filings, and a fuller ABO2203 dataset.

Sources

• Abogen: Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and Other Potential RNA Programs, PRNewswire, October 2, 2026. Primary source release.
• Abogen: AACR 2026 Oral Presentation of Preliminary ABO2203 Results in R/R B-NHL, cited for the nine-patient lymphoma safety and response data, none of which appeared in the deal release.
• Cancer Research: Abstract CT032, ABO2203 First-in-Human Study in R/R B-NHL, cited for the dose-escalation enrollment and data cutoff.
• Cell: mRNA-Encoding CD19-Targeting T Cell Engager for Refractory Immune Thrombocytopenia, cited for the three-patient ITP results and the 16-patient autoimmune enrollment figure.
• ClinicalTrials.gov: NCT06747156, ABO2203 in Refractory Autoimmune Diseases, cited for the autoimmune trial’s start date, sponsor, and design, used to check the company’s “first” claim.
• Cullinan Therapeutics: Fourth Quarter 2026 Milestones (Form 8-K, SEC EDGAR), cited for competitive context on CLN-978.
• Labiotech: Seven T Cell Engager Companies You Should Know About, cited for Candid Therapeutics’ cizutamig plans.
• Cartesian Therapeutics: Additional Retreatment Data for Descartes-08 in Myasthenia Gravis, cited for Descartes-08’s Phase 3 status and topline timing.
• Fierce Biotech: Novartis Returns to Argo for Multifaceted $5B Cardiovascular Collab, cited for Novartis’ prior Argo upfront payments used as a deal-size benchmark.
• Tracxn: Abogen Biosciences Company Profile, cited for Abogen’s private status and funding history.

Editorial Disclosure

This article reports on a licensing and option agreement between Abogen Biosciences and Novartis AG, announced in a press release issued by Abogen on October 2, 2026, regarding the mRNA-encoded T-cell engager ABO2203 and related option programs. Securities and corporate structures discussed: Novartis AG (NYSE: NVS; SIX Swiss Exchange: NOVN), Cullinan Therapeutics, Inc. (Nasdaq: CGEM), and Cartesian Therapeutics, Inc. (Nasdaq: RNAC). Abogen Biosciences and Candid Therapeutics are privately held and have no publicly traded securities. BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Abogen Biosciences, Novartis, Cullinan Therapeutics, Cartesian Therapeutics, Candid Therapeutics, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Clinical data on ABO2203, the status of competing programs, and Novartis’ prior deal terms were drawn from the AACR 2026 presentation and abstract, the Cell publication, ClinicalTrials.gov, company SEC filings and releases, and other independent sources cited above, since the original release did not address them. Statements regarding the closing of the proposed agreement, regulatory clearances, option exercises, potential milestone and royalty payments, future clinical development, and commercial prospects are forward-looking statements. They involve substantial risks, regulatory uncertainties, and scientific variables; actual outcomes, timelines, and payments may differ materially. Clinical-stage biotechnology investments carry an extreme degree of financial risk. Drug development is subject to high rates of clinical failure, regulatory rejection, and market competition, which can result in the total loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full DISCLAIMER.